Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-10-2007 | Rapid Communication

Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy

Authors: Marco Tampellini, Maria Pia Brizzi, Raffaella Bitossi, Irene Alabiso, Carla Maria Sculli, Luigi Chiusa, Mauro Papotti, Luigi Dogliotti

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2007

Abstract

Chemotherapy alone without a multimodality approach has never been demonstrated to cure metastatic colorectal cancer patients. We report the case of a young woman referred in 1999 to our institution for a pelvic relapse of rectal cancer remained stable after oxaliplatin, 5-fluorouracil, and folinic acid therapy and never grown in size up to now, more than 6 years after the last relapse. Death of all the cancer cells, neuroendocrine cells selection, or cell dormancy are some of the discussed explanations to this unique observation. An intriguing question remains open: Should this patient be considered cured?

Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 8:347–353PubMedCrossRef

Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 24(24):3939–3945PubMedCrossRef

Epstein RJ (2005) Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment. Clin Cancer Res 11:5337–5341PubMedCrossRef

Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946PubMed

Friberg S, Mattson S (1997) On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 65:284–297PubMedCrossRef

Hill GJ, Ghosh BC (1992) Late relapse and mortality in stage I large bowel cancer. J Surg Oncol 51:52–59PubMedCrossRef

Jagoditsch M, Lisborg PH, Jatzko GR, Wette V, Kropfitsch G, Denk H, Klimpfinger M, Stettner HM (2000) Long-term prognosis for colon cancer related to consistent radical surgery: multivariate analysis of clinical, surgical, and pathological variables. World J Surg 24:1264–1270PubMedCrossRef

Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476–487PubMedCrossRef

Rena O, Casadio C, Viano F, Cristofori R, Ruffini E, Filosso PL, Maggi G (2002) Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis. Twenty-year experience. Eur J Cardiothorac Surg 21:906–912PubMedCrossRef

Shia J, Tickoo SK, Guillem JG, Qin J, Nissan A, Hoos A, Stojadinovic A, Ruo L, Wong WD, Paty PB, Weiser MR, Minsky BD, Klimstra DS (2002) Increased endocrine cells in treated rectal adenocarcinomas. Am J Surg Pathol 26(7):863–872PubMedCrossRef

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237PubMedCrossRef

Title: Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy
Authors: Marco Tampellini
Maria Pia Brizzi
Raffaella Bitossi
Irene Alabiso
Carla Maria Sculli
Luigi Chiusa
Mauro Papotti
Luigi Dogliotti
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2007
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-007-0234-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2007

New approach for assessing vascular distribution within bone tumors using dynamic contrast-enhanced MRI

Screening and early diagnosis of colorectal cancer in China: a 12 year retrospect (1994–2006)

IGF-II promoter methylation and ovarian cancer prognosis

The tetraspanin superfamily member NET-6 is a new tumor suppressor gene

Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression

New experimental markers for early detection of high-risk prostate cancer: role of cell–cell adhesion and cell migration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page